Skip to search formSkip to main contentSkip to account menu

CT 2106

Known as: CT-2106, CT2106 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

polyglutamate camptothecin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors.
2015 Background: CT-2106, a camptothecin (CPT) conjugate, is a topoisomerase I inhibitor. Covalent binding through the hydroxyl… 
2004
2004
Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies.
3127 Background: CT-2106, a camptothecin (CPT) conjugate, is a new generation of topoisomerase I inhibitors designed to deliver… 
2004
2004
Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies
2073 Background: CT-2106 is a novel camptothecin (CPT) conjugate in which CPT is bound to a biodegradable water soluble poly-L… 
2004
2004
Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies.
2073 Background: CT-2106 is a novel camptothecin (CPT) conjugate in which CPT is bound to a biodegradable water soluble poly-L… 
2004
2004
504 Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)